Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
← catalyst calendarNCT07259317 · readout ≤ 407 d
Sponsored by Corcept Therapeutics (industry) · CORT — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
80estimated
Sites
16
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-27 | actual | When the study began enrolling |
| Primary completion | Sep 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Adenocarcinoma
- Carcinoma, Pancreatic Ductal
Interventions
- Drug: Relacorilant — also filed as CORT125134
- Drug: Nab-paclitaxel
- Drug: Gemcitabine
Primary outcomes
what the primary-completion date above is the date OFPercent of Patients who Experience Dose Limiting Toxicity (DLT) (Part 1)
measured Up to 28 days after the first dose of study treatment
Number of Patients with 1 or More Adverse Events (AEs) Leading to Study Drug Discontinuations or Dose Modifications (Part 1)
measured Time of first dose up to 30 days after last dose
Progression-Free Survival (PFS) (Part 2)
measured From date of enrollment until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 12 months
Permalink · CORT's whole pipeline · Catalyst calendar · Every registered study · What changed